skip to content

Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.